Cargando…

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/
https://www.ncbi.nlm.nih.gov/pubmed/34123391
http://dx.doi.org/10.1177/20552173211013831
_version_ 1783703131881734144
author van Lierop, ZYGJ
Toorop, AA
Coerver, EME
Willemse, EAJ
Strijbis, EMM
Kalkers, NF
Moraal, B
Barkhof, F
Teunissen, CE
Killestein, J
van Kempen, ZLE
author_facet van Lierop, ZYGJ
Toorop, AA
Coerver, EME
Willemse, EAJ
Strijbis, EMM
Kalkers, NF
Moraal, B
Barkhof, F
Teunissen, CE
Killestein, J
van Kempen, ZLE
author_sort van Lierop, ZYGJ
collection PubMed
description Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.
format Online
Article
Text
id pubmed-8175839
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81758392021-06-10 Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients van Lierop, ZYGJ Toorop, AA Coerver, EME Willemse, EAJ Strijbis, EMM Kalkers, NF Moraal, B Barkhof, F Teunissen, CE Killestein, J van Kempen, ZLE Mult Scler J Exp Transl Clin Brief Report Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch. SAGE Publications 2021-06-01 /pmc/articles/PMC8175839/ /pubmed/34123391 http://dx.doi.org/10.1177/20552173211013831 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Brief Report
van Lierop, ZYGJ
Toorop, AA
Coerver, EME
Willemse, EAJ
Strijbis, EMM
Kalkers, NF
Moraal, B
Barkhof, F
Teunissen, CE
Killestein, J
van Kempen, ZLE
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title_full Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title_fullStr Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title_full_unstemmed Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title_short Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
title_sort ocrelizumab after natalizumab in jc-virus positive relapsing remitting multiple sclerosis patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/
https://www.ncbi.nlm.nih.gov/pubmed/34123391
http://dx.doi.org/10.1177/20552173211013831
work_keys_str_mv AT vanlieropzygj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT tooropaa ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT coervereme ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT willemseeaj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT strijbisemm ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT kalkersnf ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT moraalb ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT barkhoff ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT teunissence ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT killesteinj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients
AT vankempenzle ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients